Fig. 1 · Structure
Documents & Downloads
ARRY-502
CRTh2 Antagonist
ARRY-502 is a potent and selective antagonist of the CRTh2 receptor, demonstrating oral bioavailability. By inhibiting PGD2-mediated Th2 inflammation, ARRY-502 effectively blocks eosinophil activation and airway hyperresponsiveness. This reagent holds significant potential for research applications focused on Th2-related asthma and related inflammatory disorders.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Antagonist |
| CAS Number | 1202891-16-4 |
| Applications | CRTh2 Antagonist |
| Formula | C26H23Cl2NO6 |
| Molecular Weight | 516.37 |
| SMILES | OC([C@@H]1C2=CC(Cl)=C(OC3=CC=C(C=C3)C(NCCC4=C(C=C(C=C4)Cl)OC)=O)C=C2OCC1)=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.